[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].

This study may make it possible for health care professionals to provide clinical QOL information on LDV/SOF therapy to patients. Furthermore, QOL information may promote decision-making for treatment, leading to effective treatment.
PMID: 31685739 [PubMed - in process]

Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - November 8, 2019 Category: Drugs & Pharmacology Authors: Aimono Y, Kohyama N, Kamoshida T, Yamamoto T, Kogo M Tags: Yakugaku Zasshi Source Type: research